Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 4;7:12044. doi: 10.1038/ncomms12044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Focal amplification of COPS5 in TCGA breast cancer. Samples were sorted by COPS5 amplitude from the IGV of TCGA portal developed by the Broad Institute. (b) Correlation of mRNA level and copy number of COPS5 in TCGA breast cancer samples. (c) COPS5 copy number and ERα mRNA expression in TCGA breast cancer samples. (d) Immunohistochemistry of COPS5 in representative tamoxifen-untreated and refractory breast cancer. Anti-COPS5 antibody showed positive staining in the nucleus of tumour cells (scale bar, 50 μm). (e) χ²-calculation of the significance of COPS5-overexpression rates in tamoxifen-refractory and tamoxifen-untreated breast tumours. (f) Growth curve of parental and tamoxifen-resistant MCF7 clones established by in vitro dose-escalation 4OHT-treatment (refer to Methods) in the presence of 2 μM of 4OHT. Values are normalized to day 0 treatment. *Significant difference compared with other samples (P<0.01 at both day 6 and day 8, Student's t-test). (g) Copy number of COPS5 genomic DNA normalized to LINE1 in parental and tamoxifen-resistant MCF7 clones. *Significant difference compared with parental MCF7 (P<0.01, Student's t-test). (h) Expression of COPS5 mRNA in parental and tamoxifen-resistant MCF7 clones. Data were normalized to GAPDH and relative to COPS5 expression in the parental cell line which was set as 1. *Significant difference compared with parental MCF7 (P<0.01, Student's t-test). (i) Western blot analysis and quantification of COPS5 protein expression in parental and tamoxifen-resistant MCF7 clones. (j) Quantitative RT–PCR analysis of ERα target genes pS2 and GREB1 in MCF7 clones after treatment with 500 nM 4OHT for 48 h. Data are presented as mean+s.e.m. of three biological replicates. *Significant difference compared with untreated parental MCF7 (P<0.01, Student's t-test).